Simplify Logo

Full-Time

Senior Director

Sales Training and Development

Confirmed live in the last 24 hours

Axsome Therapeutics Inc

Axsome Therapeutics Inc

501-1,000 employees

Develops therapies for CNS disorders

Biotechnology
Healthcare

Compensation Overview

$225k - $255kAnnually

+ Annual Bonus + Equity + Benefits Package

Senior

New York, NY, USA

On-site requirement of at least three days per week.

Category
Customer Success Management
Sales & Account Management
Required Skills
Sales
Marketing
Requirements
  • Bachelor’s Degree Required
  • 7+ years in Leadership/Organizational training in the pharmaceutical industry
  • 10+ years of previous pharmaceutical, biotech, or medical/marketing/sales/training experience with a strong knowledge of the pharmaceutical marketplace and deep understanding of the pharmaceutical industry
  • Up to 30% travel
  • Ability to work on-site Monday, Tuesday, and Thursday. We are unable to consider candidates who are looking for fully remote roles
Responsibilities
  • Spearhead Axsome’s learning and development strategy, creating a roadmap, and implementing programs that cultivate the necessary talent and skills to achieve our strategic long-term objectives across a diverse portfolio of innovative products
  • Lead and manage a training team, providing guidance, mentorship, and support. Fostering a collaborative environment that encourages skill development and knowledge sharing
  • Oversee the planning and development of workshops, both at the national and regional levels. Conduct “train-the-trainer” sessions to empower internal trainers with the necessary skills to deliver effective training
  • Take the leading role in the development and execution of frontline sales leader training and development initiatives
  • Ensure seamless integration of training materials and assessments within the LMS
  • Collaborate with cross-functional partners, including Medical, Regulatory, and Legal teams, to support development, approval and execution of training programs and resources, ensuring compliance with company policy as well as industry regulations and guidelines
Axsome Therapeutics Inc

Axsome Therapeutics Inc

View

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain to help regulate mood. This drug has shown positive results in clinical trials and has received FDA Breakthrough Therapy Designation, which speeds up its development process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and clinical trials. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.

Company Stage

IPO

Total Funding

$430.7M

Headquarters

New York City, New York

Founded

2012

Growth & Insights
Headcount

6 month growth

45%

1 year growth

45%

2 year growth

45%
Simplify Jobs

Simplify's Take

What believers are saying

  • The launch of Auvelity and the promising results of AXS-12 in Phase 3 trials indicate strong potential for revenue growth and market impact.
  • Axsome's strategic expansion of its sales force to support Auvelity's launch demonstrates its commitment to commercial success.
  • The appointment of experienced leaders like Dr. Sue Mahony to the board enhances Axsome's strategic direction and governance.

What critics are saying

  • The biopharmaceutical sector's inherent risks, including regulatory hurdles and clinical trial failures, could impact Axsome's progress.
  • High competition in the CNS disorder treatment market may challenge Axsome's ability to capture significant market share.

What makes Axsome Therapeutics Inc unique

  • Axsome Therapeutics focuses on CNS disorders with a strong emphasis on unmet medical needs, setting it apart from broader biopharmaceutical companies.
  • The FDA Breakthrough Therapy Designation for AXS-05 highlights its innovative approach and potential for rapid market entry.
  • Axsome's diversified pipeline, including treatments for MDD, TRD, Alzheimer's agitation, and narcolepsy, showcases its comprehensive strategy in CNS therapeutics.